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Optimal oxidative stress (OS) is important throughout pregnancy; however, an increased 33 
OS may alter placental angiogenesis culminating in an imbalanced of angiogenic growth 34 
mediators (AGMs). Suboptimal Health Status (SHS), a physical state between health 35 
and disease, may be associated with increased OS and unbalanced AGMs. In this study, 36 
we explored the association between SHS, biomarkers of OS (BOS) and AGMs among 37 
normotensive pregnant women (NTN-PW) in a Ghanaian Suboptimal Health Cohort 38 
Study (GHOACS). This comparative GHOACS recruited 593 NTN-PW from the Komfo 39 
Anokye Teaching Hospital, Ghana.  SHS was measured using a Suboptimal Health 40 
Status Questionnaire-25 (SHSQ-25). Along with the subjective SHS measure, objective 41 
BOS: 8-hydroxy-2-deoxyguanosine (8-OHdG), 8-epiprostaglandinF2 alpha (8-epi-42 
PGF2α), total antioxidant capacity (TAC), and AGMs: vascular endothelial growth 43 
factor-A (VEGF-A), soluble fms-like tyrosine kinase receptor 1 (sFlt-1), placenta 44 
growth factor (PIGF) and soluble endoglin (sEng) were evaluated. Compared to optimal 45 
health NTN-PW, levels of PlGF, VEGF-A and TAC were significantly (p<0.05) reduced 46 
and negatively associated with SHS whilst sEng, sFlt-1, 8-epiPGF2α, 8-OHdG, and 47 
combined ratios of sFlt-1/PlGF, 8-epiPGF2α/PlGF, 8-OHdG/PlGF, and sEng/PlGF were 48 
significantly increased and positively associated with SHS. The 1st quartile for PIGF 49 
(2.79-fold) and VEGF-A (5.35-fold), and the 4th quartile for sEng (4.31-fold), sFlt-50 
1(1.84-fold), 8-epiPGF2α (2.23-fold), 8-OHdG (1.90-fold) and urinary 8-OHdG (1.95-51 
fold) were independently associated with SHS (p<0.05). SHS is associated with 52 
increased OS and unbalanced AGMs. Early identification of SHS-related OS and 53 
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 58 
Introduction  59 
In recent years, a number of normotensive pregnant mothers, particularly in sub-60 
Saharan African (SSA) countries continue suffer health complaints without diagnosable 61 
conditions, and this has led to increased morbidity and mortality rates [1,2]. 62 
Particularly, the stressful demands during pregnancy may alter physiological and 63 
metabolic functions and lead to health complaints including high-oxygen requirement 64 
and high-energy demand [3]. Although these dramatic events occur to sustain the 65 
mother and the growing foetus, they may also culminate in oxidative stress and adverse 66 
pregnancy outcomes such as stillbirth, intrauterine growth restriction and preterm 67 
delivery among others [4,5].  68 
Oxidative stress (OS) is an imbalance between pro-oxidant and anti-oxidant 69 
capacity [6]. Meanwhile, an optimal OS and reactive oxygen species (ROS) are 70 
essential throughout pregnancy to regulate a successful placental angiogenesis; a 71 
process whereby new blood vessels are formed from pre-existing ones during vascular 72 
development [7,8]. In an optimal OS state during placental angiogenesis and maternal 73 
vascular remodeling, the extravillous cytotrophoblast (EVT) cells of foetal origin 74 
invade the maternal uterine spiral arteries [7,9]. The resultant is the formation of a large 75 
capacity conduit vessel network which allows adequate exchange of blood and nutrient 76 
between the mother and the foetus [10]. During this process, the invasive EVT 77 
expresses a number of angiogenic growth mediators (AGMs) including pro-angiogenic 78 
growth factors such as VEGF-A and PlGF, and anti-angiogenic factor like sFlt-1 [7]. 79 
Both VEGF-A and PlGF are involved in angiogenesis, placental vascular remodeling, 80 
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vascular permeability, nitric oxide (NO) production, promoting endothelial cell control 81 
and proliferation [7,8].  82 
Meanwhile, increased OS can be detrimental [6-8]. For instance, in an increased 83 
OS state, the EVT overexpresses sFlt-1, which antagonises the function of VEGF and 84 
PlGF on the endothelial cells leading to endothelial dysfunction [6,7]. Soluble endoglin 85 
(sEng), another anti-angiogenic growth factor which is highly expressed on the 86 
endothelial cells and cell membrane of the syncytiotrophoblast cells also antagonises 87 
the function of transforming growth factor beta 1 (TGFβ1), resulting in a loss of 88 
endothelial cell control, vasoconstriction and increased OS  [7,9]. The increased OS 89 
may be caused by placental hypoxia/ischaemia originating from an incomplete maternal 90 
vascular remodeling [7,8].   91 
Several other factors including advanced maternal age, increased inflammatory 92 
response, cardiovascular diseases and hormonal changes contribute to increased ROS 93 
formation and OS in the circulation [10,11]. Particularly, an altered hormonal function 94 
during pregnancy is associated with elevated phospholipid levels/phospholipid 95 
accumulation [12]. Subsequently, increased levels of phospholipids at sites where ROS 96 
are formed lead to endogenous ROS-induced lipid peroxidation [13]. In addition, 97 
increased ROS formation in circulation can cause damage to proteins and DNA and lead 98 
to protein oxidation and oxidative DNA damage, respectively [7,8]. Biomarkers of 99 
oxidative stress (BOS) 8-epiPGF2α, and 8-OHdG are formed by free radical-catalysed 100 
phospholipid peroxidation and are potent markers indicative of in-vivo OS and oxidative 101 
DNA damage, respectively [13]. A compromised antioxidant system on the other hand, 102 
depicts a correspondingly reduced level of TAC [10]. 103 
Previous studies have extensively focused on increased levels of OS and 104 
imbalance in AGMs among women with complicated pregnancies [5,14] while paying 105 
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less attention to these changes in normal pregnancies [15]. In addition to the dearth of 106 
data on evaluation of BOS and AGMs together in normal pregnancy, previous studies 107 
evaluated these markers in third trimester while paying less attention to these levels in 108 
the early trimesters of pregnancy. Early identification of increase OS and unbalanced 109 
levels of AGMs would improve diagnosis and treatment. Despite the fact that BOS and 110 
AGMs are sensitive and dynamic in both pregnancy and neonatal medicine, they are not 111 
used in routine antenatal care because they are expensive, invasive, requires a long 112 
turnaround time and expertise, and may not be readily available to women who visit 113 
under resourced hospitals. In addition, a longer turnaround time leads to delayed 114 
therapeutic interventions. An attempt to overcome this over the past few years has been 115 
the need to shift from reactive medical intervention to predictive, preventive and 116 
personalised medicine (PPPM) [16-20]. The approach of PPPM has adopted traditional, 117 
behavioural and environmental factors for early treatment and prevention of 118 
unrecognised diseases [20]. One way to identify participants with preconditions even 119 
before the onset of clinical manifestations, is to evaluate their physiological metrics at 120 
the preclinical or suboptimal health stage [19]. 121 
From the public health perspective, a recent development in the research for a 122 
promising suboptimal health status (SHS) evaluation measure that can be used in PPPM, 123 
is the development of a 25-question item Suboptimal Health Status Questionnaire 124 
(SHSQ-25). It is a subjective and non-invasive health assessment tool which is 125 
inexpensive, and requires less expertise and turnaround time. The SHSQ-25 was first 126 
created by our team and the term ‘suboptimal health status’ (SHS) was coined to define 127 
a physical state between health and disease [21,22]. SHS is recognised as a subclinical, 128 
reversible stage of chronic disease and characterised by poor health, low energy or vitality 129 
and general body weakness [19,21,22]. SHSQ-25 has since been used to evaluate SHS in 130 
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several studies and was found useful for early detection and risk stratification of several 131 
symptoms and diseases [19,23-29]. For example, SHS was found to be an independent 132 
risk factor for type II diabetes mellitus in an African population [23], arterial stiffness 133 
and cardiovascular disease in European population [24], type II diabetes mellitus [25], 134 
cardiovascular diseases [26,27], psychosocial stress [28], and telomere length [29] in an 135 
Asian population.   136 
Even though previous studies have reported a correlation of SHS with 137 
cardiovascular disease and arterial stiffness, which are both risk factors for increased 138 
oxidative stress, no study to date has explored together, its relationship with BOS and 139 
AGMs in pregnancy. Although OS and imbalance in AGMs are common in complicated 140 
pregnancies like preeclampsia, it is possible that SHS may precede it s clinical 141 
manifestation.  Our ongoing cohort study found that SHS is an independent measure for 142 
preeclampsia [30]. As a result, there is the need to evaluate if our NTN-PW 143 
experiencing suboptimal health exhibit a variation in OS and AGMs levels  compared to 144 
optimal health status NTN-PW. For the first time in the present study, we explore an 145 
association of SHS with BOS and AGMs among normotensive pregnant women at 10-146 
20 weeks gestation in a Ghanaian Suboptimal Health Cohort Study (GHOACS). An 147 
increased OS and unbalanced AGMs, if found associated with SHS, would validate the 148 
usefulness of SHSQ-25 thereby creating a possibility to inform clinicians the need for 149 
early therapeutic options. 150 
 151 
Materials and Methods  152 
Study design and participants 153 
As a part of the on-going Ghanaian Suboptimal Health Cohort Study (GHOACS), this 154 
hospital-based comparative cross-sectional study included 593 normotensive pregnant 155 
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women (NTN-PW) attending regular antenatal care at the Obstetrics and Gynaecology 156 
Department of Komfo Anokye Teaching Hospital (KATH), Kumasi Ghana.  Both 157 
nulliparous and multiparous NTN-PW aged from 18 to 45 years with a singleton 158 
pregnancy from 10 to 20 weeks gestation gave written informed consent and were 159 
included in the present study. All participants were physically examined by a qualified 160 
consultant obstetrician/gynaecologist. The normotensive pregnancy was classified as 161 
pregnancy without measurable proteinuria and had normal blood pressure (< 140/90 162 
mmHg) on two occasions at least four hours apart and had no history of a clinically 163 
diagnosed condition during the three months prior to the start of the present study. 164 
Exclusion criteria were women of advanced maternal age (>45 years), those below 18 165 
years, multiple pregnancies, previous clinically known conditions such as preeclampsia, 166 
gestational diabetes, gestational hypertension, sexually transmitted infections, sickle 167 
cell anaemia, obesity and any form of clinically diagnosed cardiovascular condition. 168 
Also, those with current or previous history of smoking and alcoholic beverage intake at 169 
the time of sampling were excluded.  170 
Ethical consideration 171 
This study was approved by the Committee on Human Research Publication and Ethics 172 
(CHRPE) of the School of Medical Science (SMS) /KNUST and Research and 173 
Development Unit, Komfo Anokye Teaching Hospital (KATH) (CHRPE/AP/146/17) 174 
and the Human Research Ethics Committee (HREC) of Edith Cowan University (ECU) 175 
(17509). Written informed consent in the form of signature and fingerprint was obtained 176 
from participants and Legally Authorised Representatives before the start of the present 177 




Suboptimal Health Status assessment and sociodemographic, clinical and obstetric 180 
data 181 
The overall SHS of NTN-PW was assessed using SHSQ-25. The SHSQ-25 consist of 182 
five subclasses namely: fatigue (9 question item), cardiovascular system (3 question 183 
item), digestive system (3 question item), immune system (3 question item) and mental 184 
health (7 question item) [19,22,31]. These questions were explained to each participant 185 
in the native language by the consultant obstetrician/gynaecologist and their response 186 
were translated into English. Each pregnant woman was asked to rate her health 187 
statement on a 5-point Likert scale: never or almost never (1), occasionally (2), often 188 
(3), very often (4) and always (5) based on how often they had experienced a particular 189 
health complaint in the past 3 months. The raw scores of 1 to 5 were recoded as 0 to 4 190 
for each participant followed by a summation of the codes for the 25 answered 191 
questions. The median of the total score was recorded as the cut-off point and values ≥ 192 
the median represented ‘SHS’ (poor health) and those ˂ indicated ‘optimal health status 193 
(OHS)’ [19,22,31]. In the present study, a score ≥ 19 depicted SHS and <19 depicted 194 
OHS. A reliability test was performed on the SHSQ-25 and a Cronbach’s alpha 195 
coefficient value was found to be 0.95.  196 
Sociodemographic, clinical and obstetric data were obtained from the antenatal 197 
folder and participant’s record in the database of the KATH. Double measurements of 198 
blood pressure (BP) as well as weight, height and body mass index (BMI) were 199 
performed by trained personnel and midwives and values were recorded. The last BMI 200 





Biospecimen collection  204 
Participants provided 10-20 millilitre midstream urine samples in sterile leak-205 
proof containers. Dipstick proteinuria was determined for each participant. Samples 206 
were centrifuged at 3000 rpm for 10 minutes at 4 oC (HERMLE® Z306K, Wehingen, 207 
Germany) and the supernatants were aliquoted into two cryovials tubes (1 ml each). One 208 
millilitre of the aliquot was used to measure urine creatinine (Cr) concentrations  and the 209 
rest were stored at -80 oC (Thermo scientific ultra-low freezer) until further analysis. An 210 
overnight fasting venous blood sample (10 millilitres) were collected between 8am and 211 
11am from each of the 593 participants and were dispensed into specialised vacutainer® 212 
tubes. The serum and plasma were obtained following centrifugation at 3000 rpm for 10 213 
minutes and were separated into two cryovials each and stored at -80 oC (Thermo 214 
scientific ultra-low freezer) until assay.   215 
Haematobiochemical assay 216 
Plasma fasting blood glucose (FBG), serum triglyceride (TG), total cholesterol 217 
(TC), high density lipoprotein cholesterol (HDL-c), low density lipoprotein cholesterol 218 
(LDL-c), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma 219 
glutamyl transferase (GGT), total protein (TP), albumin (ALB), lactate dehydrogenase 220 
(LDH), alkaline phosphatase (ALP), urea, creatinine (Cr), uric acid (UA), sodium (Na), 221 
potassium (K), chloride (Cl-), magnesium (Mg) and calcium (Ca) were measured using 222 
an automatic chemistry analyser (Roche Diagnostics, COBAS INTEGRA 400 Plus, 223 
USA). Haemoglobin, red blood cell distribution width (RDW) and platelet count (PLT) 224 





Angiogenic growth mediator (AGMs) assay 228 
Serum concentrations of VEGF-A, sFlt-1, PIGF, and sEng were measured in 229 
duplicate using competitive ELISA kits from R&D System Inc. (Minneapolis, MN 230 
USA). Absorbance was measured at 450 nm wavelength using a microplate ELISA 231 
reader (Bio-Tek ELx808 microplate reader, Hayward, CA, USA). The concentrations of 232 
each biomarker were derived from standard curves from a known standard 233 
concentration of recombinant factors.  234 
Biomarkers of oxidative stress (BOS) assay 235 
Following the manufacturer’s instructions, urinary and serum 8-OHdG were 236 
analysed in duplicates using highly sensitive and competitive ELISA kits (ab201734, 237 
Abcam, China). Serum concentrations were determined by comparison to a standard 238 
curve and recorded in ng/L. The inter-and-intra assay coefficients of variation (CV) 239 
were 3.5% and 4.5%, respectively. Urinary 8-OHdG concentrations obtained from the 240 
standard curves were normalised to creatinine concentrations and recorded as ng/mg Cr.   241 
Serum 8-epi-PGF2α was analysed in duplicate using competitive ELISA kits 242 
from ELabscience, China (cat. LogE-EL-0041). The intra-and-inter assay coefficients of 243 
variation (CV) were 5.6% and 6.4%, respectively. The absorbance of both 8-epi-PGF2α 244 
and 8-OHdG was read at 450nm on a microplate reader (Bio-Tek ELx808 microplate 245 
reader, Hayward, CA, USA).  246 
TAC reagents were obtained from Sigma-Aldrich (Hong Kong, China). Plasma 247 
samples were thawed to measure TAC spectrophotometrically at 593 nm using Mindray 248 
BA-88A, China. The estimation of TAC was based on ferric reducing ability of plasma 249 
(FRAP) and the protocol as described by Benzie and Strain [32]. The absorbance was 250 
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used to obtain the concentrations after comparison to standard curves and recorded in 251 
µmol/l.  252 
Statistical analysis 253 
Normalisation of the data was performed using Kolmogorov-Smirov test. Data was 254 
presented as mean ± SD for parametric continuous variables, median (interquartile 255 
ranges) for non-parametric continuous variables and frequency (percentages) for 256 
categorical variables. Chi-square test was performed to test associations between 257 
categorical variables. The difference in mean variables between SHS and OHS was 258 
tested using an independent sample t-test. The difference in median variables between 259 
SHS and OHS was tested using the Mann Whitney U-test. A multivariate logistic 260 
regression model was performed to test risk factors associated with SHS. Linear 261 
regression models were performed to test the associations between SHS, AGMs and OS 262 
biomarkers. Data analysis was performed using R version 3.4.3 (R core Team 2017), 263 
SPSS version 24 (IBM Corp, NY, USA) and XLSTAT Premium version 2018.1 for 264 
windows. P value < 0.05 was considered statistically significant.  265 
Results 266 
Sociodemographic characteristics of NTN-PW stratified as SHS and Optimal health status  267 
The average age of the participants was 29.64 years (Table 1). A higher proportion 268 
[34.6% (205/593)] of the study participants were aged 25 to 30 years. There was no 269 
statistically significant difference between the mean ages of pregnant women with SHS 270 
compared to those with OHS (29.44 ± 5.92 vs. 29.77 ± 6.08; p = 0.5045). Overall, a higher 271 
proportion of the pregnant women had completed secondary education [40.8% (242/593)], 272 
were married [84.5% (501/593)], were Akan’s by ethnicity [87.2% (517/593)], had an 273 
informal occupation [63.2% (375/593)] and earned a low-income per month [38.8% 274 
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(230/593)]. However, there was no statistically significant difference in proportion between 275 
pregnant women with SHS compared to OHS in terms of level of education (p = 0.7577), 276 
marital status (p = 0.7000), ethnicity (p = 0.9140), occupation (p = 0.7913) and basic monthly 277 
salary income (p = 0.8384) (Table 1).  278 







(N=296) Statistics p-value 
Age (mean ± SD) (years) 29.64 ± 5.98  29.44 ± 5.92 29.77  ± 6.08 0.6678 0.5045 
Age (years)      
18-24 130(21.9) 66(22.2) 64(21.6)   
25-30 205(34.6) 110(37.0) 95(32.1)   
31-34 124(20.9) 58(19.5) 66(22.3)   
35-45 134(22.6) 63(21.2) 71(23.9)   
Highest Level of Education    1.180, 3 0.7577 
Unschooled 5(0.8) 2(0.7) 3(1.0)   
Primary 203(34.2) 100(33.7) 103(34.8)   
Secondary 242(40.8) 127(21.4) 115(38.9)   
Tertiary 143(24.1) 68(22.9) 75(25.3)   
Marital Status    0.714, 2 0.7000 
Never married 86(14.5) 42(14.1) 44(14.9)   
Married 501(84.5) 251(84.5) 250(84.5)   
Cohabiting 6(1.0) 4(1.3) 2(0.7)   
Ethnicity    0.522, 3 0.9140 
Akan 517(87.2) 273(91.9) 244(82.4)   
Ga-Adangbe 10(1.7) 6(2.0) 4(1.4)   
Mole Dagbani 49(8.2) 49(16.5) 45(15.2)   
Ewe 8(1.3) 5(1.7) 3(1.0)   
Occupation    0.468, 2 0.7913 
Unemployed 63(10.6) 34(11.4) 29(9.8)   
Formal 155(26.1) 78(26.3) 77(26.0)   
Informal 375(63.2) 185(62.3) 190(64.2)   
Basic monthly income (GH₡)    0.846, 3 0.8384 
None 63(10.6) 34(11.4) 29(9.8)   
Low (<500.0) 230(38.8) 114(38.4) 116(39.2)   
Middle (500.0-1000.0) 198(33.4) 101(34.0) 97(32.8)   
High (>1000.0) 102(17.2) 48(16.2) 54(18.2)   
Values are presented as frequency (proportion); mean ± SD (standard deviation); GH₡: Ghana cedi. Statistics is represented 280 
as Chi-square value, degree of freedom (X2, df), and t-test value (italised) 281 
 282 
 283 
Clinical, obstetrics and routine biochemical profile of NTN-PW stratified as SHS and 284 
optimal health status  285 
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 A higher proportion of pregnant women were nulliparous [39.6% (235/593)], 286 
primigravida [46.2% (274/593)], had optimal blood pressure [60.4% (358/593)] and were 287 
overweight at both pre-gestational [37.8% (224/593)] and the time of sampling [38.6% 288 
(229/593)] (Table 2). There was a statistically significant difference in proportion between 289 
pregnant women with SHS compared to OHS in terms of parity (p =0.0311), gravidity (p 290 
=0.0309), and BP (p <0.0001). In comparison to pregnant women with OHS, those with SHS 291 
had higher proportions in terms of high BP (11.4% vs. 2.0%; p <0.0001), family history of 292 
hypertension (23.2% vs. 7.1%; p <0.0001) and history of spontaneous abortion (37.0% vs. 293 
28.0%; p = 0.0282). However, there was no statistically significant difference in proportion 294 
between pregnant women with SHS compared to OHS in terms of previous caesarean section 295 
(19.5% vs. 21.6%; p = 0.5436). Consequently, there was a statistically significant difference 296 
in the mean systolic blood pressure (SBP) between pregnant women with SHS compared to 297 
OHS (p =0.0071) but no significant difference in the mean diastolic blood pressure (DBP) (p 298 
=0.1574), gestational age (p =0.9515), pre-gestation BMI (p =0.6855) and BMI at the time of 299 
sampling (p =0.7658) between groups. There were significantly reduced levels of serum Mg 300 
(p <0.0001), Ca (p <0.0001), haemoglobin (p =0.0428) and HDL-c (p =0.0481) but 301 
significantly elevated levels of AST (p <0.0001), ALT (p =0.0158), ALP (p =0.0032), GGT 302 
(p <0.0001), urea (p=0.0242), creatinine (p =0.0467), uric acid (p =0.0002) and TG (p 303 





Table 2. Obstetric, clinical and haematobiochemical characteristics of NTN-PW 309 
stratified by SHS and OHS 310 
Characteristics  Total (N=593) SHS (N=297) OHS (N=296) Statistics p-value 
Parity    8.870, 2 0.0311 
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Nulliparous (0) 235(39.6) 113(38.0) 122(41.2)   
Primiparous (1) 114(19.2) 64(21.5) 50(16.9)   
Multiparous (2-4) 244(41.2) 120(40.5) 124(41.9)   
Gravidity     6.951, 2 0.0309 
Primigravida (1) 274(46.2) 153(51.5) 121(40.9)   
Multigravida (2-4) 175(29.5) 81(27.3) 94(31.8)   
Grand multigravida (>5) 144(24.3) 63(21.2) 81(27.4)   
BP (mmHg)    54.65, 2 <0.0001 
Normal (120-129/80-84) 553(93.3) 263(88.5) 290(98.0)   
High (130-139/85-89) 40(6.7) 34(11.4) 6(2.0)   
FH of HTN (Yes) 90(15.2) 69(23.2) 21(7.1) 33.81, 1 <0.0001 
H. Spont. Abort. (Yes) 193(32.5) 110(37.0) 83(28.0) 5.083, 1 0.0282 
Previous CS (Yes) 122(20.6) 58(19.5) 64(21.6) 0.397, 1 0.5436 
Protein (<0.3g/g/24hr) 593(100.0) 297(100.0) 276(100.0)  0.9991 
GA (weeks) 16.98 ± 2.01  16.97 ± 2.08  16.98 ± 1.98 0.061 0.9515 
SBP (mmHg) 114.7 ± 10.57  115.8 ± 11.00  113 ± 10.01 2.703 0.0071 
DBP (mmHg) 72.58 ± 9.26 73.12 ± 9.31 72.04 ± 9.20 1.416 0.1574 
Pre-gest. BMI (Kg/m2) 27.04 ± 4.83 26.65 ± 4.74 27.12 ± 4.92 0.405 0.6855 
Gest. BMI (Kg/m2) 27.33 ± 4.81 27.39 ± 4.74 27.12 ± 4.92 0.298 0.7658 
Mg (mmol/l) 0.95 ± 0.19 0.91 ± 0.24 0.99 ± 0.13 5.384 <0.0001 
Ca (mmol/l)  2.18 ± 0.35 2.07 ± 0.38 2.29 ± 0.27 8.431 <0.0001 
Na (mmol/l)  136.3 ± 2.00 136.4 ± 1.99 136.2 ± 2.01 0.958 0.3384 
K (mmol/l) 4.18 ± 0.38 4.21 ± 0.45 4.17 ± 0.33 1.195 0.2326 
Cl-(mmol/l) 105.6 ± 2.32 105.5 ± 2.31 105.6 ± 2.33 0.399 0.6889 
LDH (IU/L)  173.3 ± 41.25 176.4 ± 45.14 170.1 ± 36.73 0.061 0.0605 
AST (IU/L) 15.70(13.70-20.50) 16.10(13.80-26.15) 15.20(13.60-19.30) 3504 <0.0001 
ALT (IU/L) 11.50(10.30-16.65) 12.60(10.30-18.40) 11.05(10.20-14.50) 3893 0.0158 
ALP (IU/L) 201.0(168.0-228.0) 205.0(168.0-235.0) 195.0(168.0-218.0) 3781 0.0032 
GGT (IU/L) 10.40(9.80-13.50) 11.30(10.10-15.40) 10.34(9.70-12.20) 3204 <0.0001 
Total protein (g/L) 67.98 ± 2.21 68.01 ± 2.21 67.96 ± 2.20 0.266 0.7900 
Albumin (g/L) 36.85 ± 1.27 36.88 ± 1.26 36.82 ± 1.27 0.556 0.5782 
Urea (mmol/l) 3.76 ± 1.61 3.92 ± 1.79 3.62 ± 1.39 2.260 0.0242 
Creatinine (µmol/l) 61.19 ± 13.51 62.29 ± 15.17 60.08 ± 11.53 1.995 0.0465 
Uric acid (µmol/l) 290.0 ± 46.10 297.0 ± 42.54 283.0 ± 48.48 3.748 0.0002 
Haemoglobin (g/dL) 11.65 ± 0.60 11.01 ± 0.63 11.69 ± 0.57 1.646 0.0428 
RDW-CV (%) 13.65 ± 1.25 13.66 ± 1.30 13.65 ± 1.19 0.123 0.9022 
PLT (X109 / L) 296.9 ± 86.75 290.8 ± 85.70 303.0 ± 87.51 1.718 0.0864 
FBG (mmol/L) 5.09 ± 0.74 5.12 ± 0.77 5.08 ± 0.69 0.635 0.5085 
TC (mmol/L) 4.65 ± 1.18 4.69 ± 1.23 4.61 ± 1.11 0.827 0.4088 
TG (mmol/L) 1.31 ± 0.68 1.39 ± 0.76 1.24 ± 0.58 2.706 0.0070 
HDL-c (mmol/L) 1.45 ± 0.32 1.40 ± 0.32 1.48 ± 0.34 1.898 0.0481 
LDL-c (mmol/L) 2.79 ± 1.05 2.84 ± 1.12 2.74 ± 0.98 1.171 0.2421 
Values are presented as frequency (proportion); mean ± SD (standard deviation); median (interquartile range). FH: Family 311 
history; PH: Previous history; CS: Caesarean section; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BMI: 312 
body mass index; HTN: hypertension; H. Spont. Abort: history of spontaneous abortion. Statistics is represented as Chi-313 
square value, degree of freedom (X2, df), Mann-Whitney U-test value (unitalised); t-test value (italised) 314 




Relationship between SHS and biochemical risk factors 317 
As shown in Table 3, after adjusting for confounding factors using a multivariate 318 
logistic regression model, the association remained significant with high BP [aOR=5.96, 95% 319 
CI (2.39-14.85); p<0.0001], low Mg [aOR=4.47, 95% CI (3.16-10.15); p<0.0001], low Ca 320 
[aOR=2.19, 95% CI(1.19-5.03), p<0.0001], high LDH [aOR= 2.75(1.60-5.07), p=0.0006], 321 
high AST [aOR=2.22(1.68-8.14), p=0.0018], high  creatinine [aOR=3.15, 95% CI (1.55-322 
7.04), p=0.0028], anaemia [aOR=1.58, 95% CI (1.11-2.62), p=0.0397] , high TG [aOR=2.14, 323 
95% CI (1.08-4.79), p=0.0206] and low HDL-c [aOR=2.57, 95% CI (1.15-7.05), p=0.0418] 324 



















Table 3. Univariate and multivariate logistic regression model of clinical and 342 
haematobiochemical profile as risks factors for SHS  343 
   Model 1  Model 2  
Characteristics SHS  OHS  cOR (95% CI) P value aOR (95% CI) P value 
BP (mmHg)       
Optimal Normal 263(88.6) 290(98.0) 1.00  1.00  
High  34(11.4) 6(2.0) 6.6(2.74-15.96) < 0.0001 5.96(2.39-14.85) < 0.0001 
Mg (mmol/l)       
Low 50(16.8) 8(2.7) 5.28(3.37-11.67) <0.0001 4.47(3.16-10.15) <0.0001 
Normal 247(83.2) 288(97.3) 1.00  1.00  
Alb. Adj. Ca (mmol/l)       
Low 159(53.5) 70(23.6) 2.72(1.61-5.29) <0.0001 2.19(1.19-5.03) <0.0001 
Normal 138(46.5) 226(76.4) 1.00  1.00  
LDH (IU/L)       
High 50(16.8) 20(6.8) 2.79(1.62-4.82) 0.0002 2.75(1.60-5.07) 0.0006 
Normal 247(83.2) 276(93.2) 1.00  1.00  
AST (IU/L)       
High 24(8.1) 6(2.0) 2.25(1.71-9.56) 0.0011 2.22(1.68-8.14) 0.0018 
Normal 273(91.9) 290(98.0) 1.00  1.00  
ALP (IU/L)       
High 82(27.6) 79(26.7) 1.04(0.72-1.50) 0.8536 1.08(0.78-1.93) 0.8054 
Normal 215(72.4) 217(73.3) 1.00  1.00  
Urea (IU/L)       
High 12(4.0) 4(1.4) 3.07(0.97-9.64) 0.0729 3.03(0.73-10.51) 0.0910 
Normal 285(96.0) 292(98.6) 1.00  1.00  
Creatinine (IU/L)       
High 32(10.8) 11(3.7) 3.12(1.54-6.33) 0.0013 3.15(1.55-7.04) 0.0028 
Normal 265(89.2) 285(96.3) 1.00  1.00  
Uric acid (µmol/l)       
High 10(3.4) 8(2.7) 1.25(0.48-3.22) 0.8117 1.18(0.41-3.88) 0.8531 
Normal 287(96.6) 288(97.3) 1.00  1.00  
Hb (g/dl)       
Anemia 80(26.9) 57(19.3) 1.55(1.05-2.27) 0.0319 1.58(1.11-2.62) 0.0397 
Non-anemia 217(73.1) 239(80.7) 1.00  1.00  
FBS (mmol/L)       
High Normal 27(9.1) 16(5.4) 1.75(0.92-3.32) 0.1124 1.85(0.81-3.85) 0.1068 
Normal 270(90.9) 280(94.6) 1.00  1.00  
TC (mmol/L)       
High 91(30.6) 76(25.7) 1.27(0.89-1.83) 0.2013 1.30(0.94-2.03) 0.2750 
Desirable 206(69.4) 220(74.3) 1.00  1.00  
TG (mmol/L)       
High 30(10.1) 14(4.7) 2.26(1.17-4.36) 0.0179 2.14(1.08-4.79) 0.0206 
Normal 267(89.8) 282(95.3) 1.00  1.00  
HDL-c (mmol/L)       
Low 18(6.1) 7(2.4) 2.66(1.09-6.47) 0.0390 2.57(1.15-7.05) 0.0418 
Normal 279(93.9) 289(97.6) 1.00  1.00  
LDL-c (mmol/L)       
High 54(18.2) 37(12.5) 1.55(0.98-2.44) 0.0679 1.38(0.689-2.67) 0.0890 
Normal 243(81.8) 259(87.5) 1.00  1.00  
cOR: Crude odds ratio; aOR: adjusted odds ratio; CI: confidence interval; 1.00: reference category; Model 1:unadjusted odds 344 
ratio; Model 2 adjusted for maternal age, gestational age, parity, gravidity,  family history of hypertension , maternal  BP, 345 




Biomarkers of Oxidative stress and angiogenic growth mediators of NTN-PW 348 
stratified by SHS and Optimal health status  349 
As shown in Figure 1, there were statistically significantly increased urinary 8-OHdG 350 
(p <0.0001) and serum levels of sEng (p <0.0001), sFlt-1 (p <0.0001), 8-isoPGF2α (p 351 
<0.0001), 8-OHdG (p <0.0001), sFlt-1: PlGF ratio (p <0.0001), sEng: PlGF ratio (p 352 
<0.0001), 8-isoPGF2α: PlGF ratio (p <0.0001) and 8-OHdG: PlGF ratio (p <0.0001) among 353 
pregnant women with SHS compared to those with OHS. Conversely, there were statistically 354 
significant low serum levels of PlGF (p <0.0001) and VEGF-A (p <0.0001) among pregnant 355 
women with SHS compared to those with OHS. However, the serum levels of TAC were low 356 
in pregnant women with SHS compared to those with OHS although there was no statistically 357 




Figure 1. Density (A) and violin (B) plots of individual and combined levels of AGMs and 360 
BOS levels stratified by SHS and OHS NTN-PW  361 
PIGF: placental growth factor; VEGF-A: Vascular endothelial growth factor-A; sEng: soluble endoglin; sFlt-1: 362 
soluble fms-like tyrosine kinase-1; 8-epiPGF2 α: 8-epiprostaglandin F2 alpha; 8-OHdG: 8-hydroxy-2-deoxyguanosine; 363 





Relationship between the individual SHS-specific domains score and biomarkers of 367 
oxidative stress and angiogenic growth mediators 368 
As summarised in Table 4, the individual SHS domains such as fatigue, cardiovascular 369 
system, immune system and mental health were significant (p < 0.05) and negatively 370 
associated with PlGF and VEGF-A, but positively associated with sEng, sFlt-1, 8-epiPGF2α, 371 
8-OHdG, sFlt-1/PlGF ratio 8-epiPGF2α/PlGF ratio, 8-OHdG/PlGF ratio and sEng/PlGF ratio. 372 
The SHS-specific domain, ‘digestive system’ showed the same pattern of results except that 373 
there was no significant association with 8-OHdG. TAC was non-significant but negatively 374 
associated the individual SHS domains except for the SHS-specific domain, ‘immune 375 
system’, which showed a significant association. The multivariate model showed that 14.0% 376 
variation in SHS was explained when all the significant independent markers were included 377 













Table 4. Univariate and multivariate linear regression model for individual domain of SHS score in association with obstetric-related 389 
factors, clinical, AGMs and BOS 390 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                              391 
Sβ (R2): Standardised regression coefficient (Coefficient of determination); SBP: systolic blood pressure; DBP: diastolic blood pressure, PIGF: placental growth factor; VEGF-A: Vascular 392 
endothelial growth factor-A; sEng: soluble endoglin; sFlt-1: soluble fms-like tyrosine kinase-1; 8-epiPGF2 α: 8-epiprostaglandin F2 alpha; 8-OHdG: 8-hydroxy-2-deoxyguanosine; TAC: Total 393 












Overall SHS  
Parameters (N=593) Sβ  (R2) p-Value Sβ  (R2) p-Value Sβ  (R2)  p-Value Sβ  (R2) p-Value Sβ  (R2) p-Value Sβ  (R2) p-Value 
Model 1              
Age (years) -0.007(0.0%)  0.8521 -0.014 (0.0%) 0.7369 -0.020 (0.0%)  0.6239 -0.003 (0.0%)  0.9422 -0.068 (0.5%) 0.0982 -0.034(0.2%) 0.4560 
parity -0.009(0.0%)  0.3593 -0.072 (0.5%) 0.0788 -0.015 (0.0%)  0.7144 0.006 (0.0%) 0.8443 -0.028 (0.0%)  0.4969 -0.045(0.2%) 0.2771 
gravidity -0.003(0.0%)  0.8113 -0.079 (0.6%) 0.0526 -0.026 (0.0%) 0.5232 -0.028 (0.0%)  0.4949 -0.067 (0.5%)  0.1027 -0.051(0.3%) 0.2120 
Gest. Age (Weeks) -0.001(0.0%)  0.9683 -0.001 (0.0%)  0.9879 -0.022 (0.0%)  0.5896 0.014 (0.0%) 0.7394 -0.007 (0.0%) 0.8623 -0.005(0.1%) 0.9040 
SBP (mmHg) 0.077(0.6%)  0.0616 0.090 (0.8%) 0.0281 0.058 (0.3%)  0.1579 0.130 (1.7%)  0.0015 0.148 (2.2%)  0.0003 0.144(2.1%) 0.0004 
DBP (mmHg) -0.009(0.0%)  0.8285 0.036 (0.1%) 0.3814 -0.001 (0.0%)  0.9781 0.067 (0.5%) 0.1042 0.183 (3.3%) < 0.0001 0.086(0.6%) 0.0375 
Gestational BMI -0.004(0.0%)  0.8980 0.084 (0.7%)  0.0400 0.060 (0.4%) 0.1442 0.017 (0.0%) 0.6834 0.038 (0.1%)  0.3499 0.038(0.1%) 0.3608 
Pre-gestation BMI -0.029(0.1%)  0.4745 0.186 (0.5%) 0.0867 0.046 (0.2%)  0.2673 0.001 (0.0%) 0.9685 0.022 (0.0%)  0.5990 0.010(0.0%) 0.8064 
PIGF (pg/mL) -0.123(1.5%)  0.0028 -0.114 (1.3%) 0.0054 -0.150 (2.3%)  0.0002 -0.167 (2.8%) < 0.0001 -0.175 (3.1%)  < 0.0001 -0.207(4.3%) <0.0001 
VEGF-A(pg/mL) -0.142(2.0%)  0.0005 -0.143 (2.0%) 0.0005 -0.140 (2.0%)  0.0006 -0.164 (2.7%) < 0.0001 -0.202 (4.1%)  < 0.0001 -0.230(5.3%) <0.0001 
sEng (ng/mL) 0.186(3.5%)  < 0.0001 0.101 (1.0%) 0.0137 0.087 (0.8%)  0.0333 0.097 (1.0%)  0.0177 0.155 (2.4%) 0.0002 0.212(4.5%) <0.0001 
sFlt-1 (pg/ml) 0.182(3.3%)  < 0.0001 0.155 (2.4%) 0.0001 0.162 (2.6%)  < 0.0001 0.209 (4.4%)  < 0.0001 0.208 (4.3%) < 0.0001 0.270(7.3%) <0.0001 
8-epiPGF2α(pg/ml) 0.139(1.9%)  0.0007 0.138 (1.9%) 0.0008 0.136 (1.8%)  0.0009 0.148 (2.2%)  0.0003 0.206 (4.3%) < 0.0001 0.225(5.1%) <0.0001 
8-OHdG(ng/mgCr) 0.119(1.4%)  0.0037 0.110 (1.2%) 0.0073 0.058 (0.3%) 0.1683 0.128 (1.6%) 0.0019 0.158 (2.5%) 0.0001 0.175(3.1%) <0.0001 
U8-OHdG(ng/ml) 0.125(1.6%) 0.0023 0.101 (1.0%) 0.0134 0.069 (0.5%)  0.0956 0.140 (2.0%)  0.0006 0.151 (2.3%)  0.0002 0.178(3.2%) <0.0001 
TAC (µmol/L) -0.062(0.4%)  0.1301 -0.002 (0.0%) 0.9560 -0.003 (0.0%)  0.9345 -0.100 (1.0%)  0.0178 -0.045 (0.2%) 0.2775 -0.072(0.5%) 0.0883 
sFlt-1: PIGF ratio 0.177(3.2%) < 0.0001 0.205 (4.2%) < 0.0001 0.167 (2.8%) < 0.0001 0.248 (6.1%) < 0.0001 0.233 (5.4%) < 0.0001 0.292(8.5%) <0.0001 
sEng: PIGF ratio 0.160(2.6%) < 0.0001 0.149 (2.2%) 0.0003 0.140 (2.0%) 0.0006 0.194 (3.8%) < 0.0001 0.193 (3.7%) < 0.0001 0.244(6.0%) <0.0001 
8-epiPGF2α: PIGF 0.146(2.1%) 0.0004 0.187 (3.5%) < 0.0001 0.163 (2.7%) < 0.0001 0.223 (5.0%) < 0.0001 0.223 (5.0%) < 0.0001 0.262(6.9%) <0.0001 
8-OHdG: PIGF 0.141(2.0%) 0.0006 0.167 (2.8%) < 0.0001 0.159 (2.5%) < 0.0001 0.219 (4.8%) < 0.0001 0.211 (4.4%) < 0.0001 0.250(6.3%) <0.0001 
Model 2              
R2 7.2%  5.1%  5.0%  10.7%  11.4%  14.0%  
Adjusted R2 5.5%  2.9%  3.5%  8.8%  9.4%  12.2%  
Constant             
p-value <0.0001  0.0042  0.0004  <0.0001  <0.0001  <0.0001  
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Relationship between the overall SHS score and individual biomarkers of oxidative stress 395 
and angiogenic growth mediators 396 
There was a significantly negative association between SHS and serum PlGF (sβ = -397 
0.207; R²=4.3%; p <0.0001) and VEGF-A (sβ = -0.230; R²=5.3%; p <0.0001) but a 398 
significantly positive association with sEng (sβ = 0.212; R²= 4.5%; p <0.0001), and sFlt-1 (sβ 399 
= 0.270; R²=7.3%; p <0.0001) There was a significantly positive association between SHS 400 
and serum 8-epiPGF2α (sβ = 0.225; R²=5.1%; p <0.0001), serum 8-OHdG (sβ = 0.175; R²= 401 
3.1%; p <0.0001), and urinary 8-OHdG (sβ = 0.179; R²=3.2%; p <0.0001) but a negative 402 






Figure 2. Linear regression model of SHS score in association with levels of AGMs and BOS among NTN-PW  407 
Uβ: unstandardised co-efficient; Sβ: standardised co-efficient; SE: standard error; R2: coefficient of determination. Significant negative association between SHS and serum PlGF (Sβ = -0.207; 408 
p<0.0001) (Figure 2a); and VEGF-A (Sβ = -0.230; p <0.0001) (Figure 2b). Significant positive association between SHS and sEng (Sβ = 0.212; p <0.0001) (Figure 2c); sFlt-1 (Sβ = 0.270; p 409 
<0.0001) (Figure 2d); serum 8-epiPGF2α (Sβ = 0.225; p <0.0001) (Figure 2e); serum 8-OHdG (Sβ = 0.175; p <0.0001) (Figure 2f) and urinary 8-OHdG (Sβ = 0.179; p <0.0001) (Figure 2g).  410 
Non-significant negative relationship between SHS and TAC (Sβ = -0.720; R²= 0.5%; p =0.0883) (Figure 2h) 411 
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Relationship between the overall SHS score and combined biomarkers of oxidative stress 412 
and angiogenic growth mediators 413 
 As shown in Figure 3, there was a significantly positive relationship between SHS 414 
and sFlt-1: PlGF ratio (sβ = 0.292; R²=8.5%; p <0.0001), 8-epiPGF2α: PlGF ratio (sβ = 0.262; 415 
R²=6.9%; p <0.0001), 8-OHdG: PlGF ratio (sβ = 0.250; R²=6.3%; p <0.0001), sEng: PlGF 416 
ratio (sβ = 0.244; R²=6.0%; p <0.0001), SBP (sβ = 0.144; R²=2.1%; p =0.0004) and DBP (sβ 417 






Figure 3. Linear regression model of SHS score in association with ratios of AGMs and 422 
BOS and BP among NTN-PW  423 
Uβ: unstandardised co-efficient; Sβ: standardised co-efficient; SE: standard error; R2: coefficient of determination. Significant 424 
positive association between SHS and sFlt-1: PlGF ratio (Sβ = 0.292; p <0.0001) (Figure 3a); sEng: PlGF ratio (Sβ = 0.244; p 425 
<0.0001) (Figure 3b), 8-epiPGF2α: PlGF ratio (Sβ = 0.262; p <0.0001) (Figure 3c), 8-OHdG: PlGF ratio (Sβ = 0.250; p 426 





Predictive odds ratios of the individual biomarkers of oxidative stress and angiogenic 430 
growth mediators in association with SHS 431 
 As shown in Table 5 the 1st quartiles for serum PIGF [aOR=2.79; 95% CI (1.43 to 432 
3.28); p = 0.0002] and VEGF-A [aOR =5.35; 95%CI (2.85 to 10.01); p <0.0001], the 2nd 433 
quartile for PIGF [aOR =2.48; 95%CI (1.28 to 5.29)]; p =0.0154) and the 4th quartiles for 434 
sEng [aOR =4.31; 95% CI (2.37 to 7.81); p <0.0001], sFlt-1[aOR =1.84; 95% CI (1.15 to 435 
2.83); p = 0.0013], 8-epiPGF2α [aOR =2.23; 95% CI (1.41 to 3.46); p = 0.0001], serum 8-436 
OHdG [aOR =1.90; 95% CI (1.28 to 2.83); p =0.0018] and urinary 8-OHdG [aOR =1.95; 437 
95% CI (1.30 to 2.90); p = 0.0004] were independently associated with SHS with only few 438 














Table 5. Crude and adjusted odds ratios of quartile for AGMs and BOS associated with 451 






Crudes odds ratio  
 (95% CI) p-value 
adjusted odds ratio  
(95% CI) p-value 
Serum PIGF (pg/ml)        
Q1 (<80.10) 91(30.6) 56(18.9) 2.12(1.39 to 3.24) 0.0005 2.79(1.43 to 3.28) 0.0002 
Q2 (80.10-89.10) 27(9.1) 14(4.7) 2.52(1.26 to 5.05) 0.0104 2.48(1.28 to 5.29) 0.0154 
Q3 (89.11-99.10) 78(26.3) 94(31.8) 1.08(0.73 to 1.61) 0.7615 1.13(0.81 to 1.77) 0.4382 
Q4 (>99.11) 101(34.0) 132(44.6) 1.00  1.00  
Serum VEGF-A (pg/ml)       
Q1 (<124.4) 108(36.4) 40(13.5) 5.31(2.98 to 9.43) < 0.0001 5.35(2.85 to 10.01) < 0.0001 
Q2 (124.4-163.4) 45(15.1) 50(16.9) 1.76(0.96 to 3.22) 0.0704 1.63(0.91 to 3.25) 0.0816 
Q3 (163.5-203.4) 115(38.7) 149(50.3) 1.51(0.91 to 2.52) 0.1299 1.39(0.60 to 2.81) 0.3014 
Q4 (>203.5) 29(9.8) 57(19.3) 1.00  1.00  
Serum sEng (ng/ml)        
Q1 (<3.194) 65(21.9) 83(28.0) 1.00  1.00  
Q2 (3.194-5.194) 106(35.7) 114(23.6) 1.19(0.78 to 1.81) 0.4563 1.15(0.76 to 1.82) 0.5035 
Q3 (5.195-7.195) 59(19.9) 79(26.7) 0.95(0.59 to 1.52) 0.9051 1.07(0.64 to 1.69) 0.9713 
Q4 (>7.196) 67(22.6) 20(6.8) 4.28(2.35 to 7.76) < 0.0001 4.31(2.37 to 7.81) < 0.0001 
Serum sFlt-1 (pg/ml)        
Q1 (<441.3) 69(23.2) 78(26.4) 1.00  1.00  
Q2 (441.3-561.3) 62(20.9) 83(28.0) 0.84(0.53 to 1.34) 0.4827 0.88(0.51 to 1.40) 0.3016 
Q3 (561.4-681.4) 40(13.5) 57(19.3) 0.79(0.47 to 1.33) 0.4305 0.80(0.48 to 1.35) 0.3580 
Q4 (>681.5) 126(42.4) 78(26.4) 1.83(1.18 to 2.81) 0.0066 1.84(1.15 to 2.83) 0.0013 
Serum 8-epiPGF2α (pg/ml)        
Q1 (<295.0) 64(21.5) 84(28.4) 1.00  1.00  
Q2( 295.0-394.0) 64(21.5) 81(27.4) 1.04(0.65 to 1.64) 0.9066 1.13(0.58 to 1.66) 0.9801 
Q3 (395.0-494.0) 60(20.2) 66(22.3) 1.19(0.74 to 1.92) 0.5427 1.16(0.70 to 1.97) 0.4911 
Q4 (>495.0) 109(36.7) 65(21.9) 2.20(1.40 to 3.44) 0.0005 2.23(1.41 to 3.46) 0.0001 
Serum 8-OHdG (ng/L)       
Q1(<61.40) 61(20.5) 87(29.4) 1.00  1.00  
Q2(61.40-71.40) 21(7.1) 24(8.1) 1.24(0.63 to 2.44) 0.6059 1.21(0.67 to 2.53) 0.5473 
Q3(71.50-81.50) 51(17.2) 61(20.6) 1.19(0.73 to 1.96) 0.528 1.15(0.69 to 1.98) 0.6014 
Q4(>81.60) 164(55.2) 124(41.9) 1.89(1.26 to 2.82) 0.0024 1.90(1.28 to 2.83) 0.0018 
Urinary 8-OHdG (ng/mg Cr)       
Q1 (<59.95) 61(20.5) 87(29.4) 1.00  1.00  
Q2 (59.95-69.95) 21(7.1) 21(7.1) 1.43(0.72 to 2.83) 0.3779 1.42(0.71 to 2.85) 0.3506 
Q3 (69.96-79.96) 52(17.5) 67(22.6) 1.11(0.68 to 1.80) 0.7097 1.18(0.64 to 1.81) 0.6937 
Q4(>79.97) 163(54.9) 121(40.9) 1.92(1.28 to 2.87) 0.0016 1.95(1.30 to 2.90) 0.0004 
Plasma TAC (µmol/L)       
Q1 (<178.9) 78(26.3) 70(23.6) 1.20(0.82 to 1.77) 0.3749 1.48(0.99 to 1.76) 0.0504 
Q2 (178.9-198.9) 37(12.5) 28(9.5) 1.43(0.84 to 2.44) 0.2228 1.41(0.81 to 1.71) 0.3001 
Q3 (199.9-219.9) 21(7.1) 24(8.1) 0.95(0.51 to 1.76) 0.8753 0.98(0.51 to 1.78) 0.7937 
Q4 (>220.9) 161(54.2) 174(58.8) 1.00  1.00  
Values are presented as frequency (proportion); odds ratio (95% confidence intervals). 1.00 (reference category). Q: quartile. 453 
PIGF: placental growth factor; VEGF-A: Vascular endothelial growth factor-A; sEng: soluble endoglin; sFlt-1: soluble fms-454 
like tyrosine kinase-1; 8-epiPGF2 α: 8-epiprostaglandin F2 alpha; 8-OHdG: 8-hydroxy-2-deoxyguanosine; TAC: Total 455 
antioxidant capacity. Covariate of adjusted model include maternal age, parity, gravidity, high BP, family history of 456 
hypertension, history of spontaneous abortion, pre-gestational BMI, high TG, AST, LDH, creatinine, and low Hb, low HDL, 457 








Using the subjective and non-invasive SHSQ-25, we stratified the health status of NTN-PW 464 
into SHS and optimal health status (OHS), compared the levels of OS and AGMs in these 465 
SHS and OHS groups and further tested the association between SHS and these biomarkers 466 
by performing a linear regression and multivariate logistic regression model. Overall, our 467 
novel findings indicated that the higher the SHS score, the more deranged the levels of BOS 468 
and AGMs, and this was further confirmed by a significant independent association between 469 
them after adjusting for confounding factors: maternal age, parity, gravidity, high BP, family 470 
history of hypertension, history of spontaneous abortion, pre-gestational BMI, high TG, AST, 471 
LDH, creatinine, and low Hb, HDL, Mg and Ca.  472 
Particularly, NTN-PW with SHS had significantly increased OS biomarkers as 473 
depicted by increased levels of the pro-oxidants (8-OHdG, 8-epiPGF2α) and a fairly reduced 474 
antioxidant (TAC) (Figure 1). This was confirmed by a significant positive association 475 
between SHS and 8-OHdG and 8-epiPGF2α but a negative association with TAC, which 476 
means that SHS increases with increasing pro-oxidant activity and a reduced anti-oxidant 477 
system. This finding might be indicative of increased oxidative DNA damage, endogenous 478 
oxidative stress and a compromised anti-oxidant system [8]. Previous studies have also 479 
explained that an incomplete maternal vascular artery remodeling results in placental 480 
hypoxia/ischaemia, which eventually leads to OS [6,8]. Cardiovascular risk factors including 481 
dyslipidaemia and hypertension have also been linked to OS [33,34].  Hormonal imbalances 482 
are commonly associated with pregnancy and it is reported to contribute to increased 483 
phospholipid accumulation [12]. In the present study, cardiovascular indicators such as high 484 
triglyceride, low HDL-c and high BP were found to be independent risk factors for SHS 485 
(Table 3). The association was confirmed by positive correlation between the SHS-specific 486 
domain, ‘cardiovascular system’ and unbalanced BOS (Table 4). This finding is consistent 487 
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with a cross-sectional study conducted in a Chinese population which observed an association 488 
between SHS and ideal cardiovascular health metrics [26]. The observed increased OS 489 
among SHS individuals may further be explained by these cardiovascular risk factors 490 
associated with SHS. Hormonal imbalances are commonly associated with pregnancy and it 491 
is reported to contribute to increased phospholipid accumulation [12]. Increased lipids at 492 
sites where ROS are formed can result in endogenous lipid peroxidation [12]. Hence, 493 
the observed increased OS among SHS NTN-PW may possibly be due to ROS-induced lipid 494 
peroxidation [12]. In order to understand the strength of the association between OS and 495 
SHS, we adjusted for the significant haematobiochemical, clinical and obstetrics factors 496 
associated with SHS. Interestingly, the association between SHS and OS biomarkers still 497 
remained significant with slight variations in the odds ratios, indicating that the association is 498 
independent of confounding factors. Particularly as shown in Table 5, the fourth quartile for 499 
serum 8-epiPGF2α, serum 8-OHdG and urinary 8-OHdG showed a 2.23-fold, 1.90-fold and 500 
1.95-fold increased adjusted odds of SHS compared to the first quartile levels. This finding 501 
makes SHS an independent risk factor for OS. We therefore hypothesize that SHS is 502 
associated with increased OS and poor maternal vascular remodeling compared to pregnant 503 
women with optimal health. This would inform clinicians the need for a combined 504 
antioxidant supplement and pro-angiogenic molecules. Evaluation of SHS criterion can create 505 
an opportunity for predictive, preventive and personalised medicine.  506 
Increased OS during normotensive pregnancy, although not well understood may also 507 
be attributed to several mechanisms. For instance, maternal anaemia is reported as one major 508 
risk factor that contributes significantly to increase OS [3]. In the present study, the 509 
significant association between maternal low haemoglobin levels and SHS may be a 510 
contributing factor for the observed increased OS among SHS compared to optimal health 511 
NTN-PW; however, the relationship between OS and SHS was independent of anaemia. 512 
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Also, psychosocial stress which is a health complaint commonly among pregnant has been 513 
linked with OS [4]. A cross-sectional study among normal pregnant women reported that an 514 
increased OS may be associated with maternal psychosocial stress [4]. Another cross-515 
sectional study among an adult Chinese population also found a significant relationship 516 
between SHS and psychosocial stress [28]. In the present study, ‘fatigue’, which is an index 517 
of psychosocial stress, and also one of the SHS domains was associated with increased OS 518 
and a compromised antioxidant system (Table 4). The observed OS among SHS participants 519 
may be somewhat due to its association with the SHS domain, ‘fatigue’. Increased OS has 520 
also been associated with dietary magnesium (Mg) and calcium (Ca) deficiencies [35,36], 521 
even though the associations are still debateable. In the present study, low Mg and Ca levels 522 
were significantly associated with SHS. Decreased Mg and Ca levels stimulate increased 523 
release of catecholamine, which can further increase the production and formation of ROS 524 
and result into OS [37]. In addition, Mg deficiency may induce ROS formation and lead to 525 
OS via activation of the renin-angiotensin-aldosterone system (RAAS) [37]. Mg deficiency is 526 
also reported as an early marker of endothelial dysfunction, which is also a complication of 527 
OS [35,36].  The relationship between SHS and increased OS observed in the present study 528 
may partly be due to the hypomagnesaemia and hypocalcaemia observed among SHS 529 
participants. Thus, early identification of SHS along with low Mg and Ca levels can inform 530 
clinicians of the pregnant women who stand the risk of increased OS, thus allowing the need 531 
to administer magnesium and calcium supplementations to prevent OS and possible adverse 532 
perinatal outcome.  533 
Another major novel finding in the present study was the significantly reduced PlGF 534 
and VEGF-A levels and a correspondingly increased sFlt-1 and sEng among SHS compared 535 
to optimal health NTN-PW (Figure 1). This finding signifies that SHS NTN-PW may have 536 
suffered an overexpression of anti-angiogenic growth mediators which has in turn interfered 537 
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with the pro-angiogenic function. The imbalance in AGMs observed in the present study was 538 
further confirmed by a significantly negative association of SHS with PIGF and VEGF-A, but 539 
a positive association with sFlt-1 and sEng (Figure 2). These imbalances could possibly be 540 
explained as a local placental ischaemia originating from incomplete maternal vascular 541 
remodeling which has increased systemic OS culminating in a shift in function in favour of 542 
sFlt-1 [7]. Increased OS is reported to stimulate the antagonistic activity of sFlt-1, which in 543 
turn neutralises the function of VEGF-A and PlGF [7,8].  The increased OS and unbalanced 544 
AGMs among SHS NTN-PW is a clear indication of a compromised immune health, as both 545 
factors play important role in the immune response of pregnancy. Our present study found an 546 
association between the SHS-specific domain, ‘immune system’, and increased OS and 547 
imbalance in pro-and anti-AGMs (Table 4).  548 
Also, the reduced PIGF and VEGF-A concentration and increased anti-AGMs (sFlt-1 549 
and sEng) observed among SHS NTN-PW in the present study can be linked to an event of 550 
endothelial dysfunction. While VEGF-A is an essential factor for regulating the endothelium, 551 
sEng may interfere with endothelial control by inhibiting the function of TGFβ1, which plays 552 
a central role in nitric oxide (NO) production and vasodilation [8]. The relationship between 553 
SHS and an imbalance in AGMs may be explained by the increased OS observed among SHS 554 
participants. A cross-sectional study found a significant association between SHS and 555 
endothelial dysfunction in an adult Russian population [24]. Endothelial dysfunction, 556 
although mostly associated with preeclamptic pregnancies can also be associated with 557 
uncomplicated pregnancies due to physiological adaptations [38].  The first quartile for 558 
VEGF-A and PIGF and the fourth quartile for sFlt-1 and sEng were independently associated 559 
with SHS. The first quartile for VEGF-A and PIGF were 5.35 and 2.79 times, and sFlt-1 and 560 
sEng were 1.84 and 4.31 times increased adjusted odds of SHS, respectively (Table 5). This 561 
supports our findings that SHS is associated with an imbalance in AGMs in pregnancy and 562 
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thus, incorporating SHSQ-25 as a tool in early antenatal health screening can be used as a 563 
risk stratification for abnormal maternal vascular remodeling and placental angiogenesis. 564 
This can create an opportunity for clinicians to detect early and administer appropriate 565 
medicinal intervention such as angiogenic molecules to SHS pregnant women to prevent 566 
likely adverse pregnancy outcomes.  567 
Previous studies have reported that an algorithm of markers explain and predict better 568 
the physiological variation in a condition compared using the individual markers [8,39]. In 569 
the present study, we created a novel combined OS/AGMs ratio: 8-epiPGF2/PlGF and 8-570 
OHdG/PIGF in addition to the previously known ratios: sFlt-1/PlGF and sEng/PIGF. There 571 
were significantly increased levels of sFlt-1/PlGF, 8-epiPGF2/PlGF, 8-OHdG/PIGF and 572 
sEng/PIGF ratios among SHS compared to OHS NTN-PW (Figure 1). Based on this finding, 573 
we performed a linear regression model and found a significantly positive association 574 
between these ratios and SHS. A higher percentage coefficient of variation in SHS was 575 
explained by these combined markers compared to using the individual markers (Figure 3). 576 
Increased levels of these combined markers among SHS NTN-PW support our present study 577 
findings that an imbalance in AGMs and increased OS are associated with SHS. Hence, we 578 
hypothesize that these combined panel markers can be used as a potential diagnostic tool for 579 
OS-induced abnormal placental angiogenesis and are likely to be useful generic markers of 580 
adverse pregnancy outcomes. The observed association signifies that SHS, oxidative stress 581 
and placental angiogenesis may exhibit a synergistic physiological function.  582 
While the findings in the present study are novel, there were some limitations. 583 
Firstly, because the present study is a cross-sectional hospital-based study, our results 584 
cannot be generalised for the entire population. Nevertheless, this study is the baseline 585 
of an ongoing prospective GHOACS. Aside from these limitations, there were some 586 
strengths to highlight. This is the first cross-sectional study which sought to ascertain if 587 
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SHS is associated with increased OS and unbalanced AGMs among normotensive 588 
pregnant women in a Ghanaian. Another strength of the present study finding was that 589 
the association remained significant after adjusting for confounding factors, indicat ing 590 
that SHS is an independent risk factor of increased OS and unbalanced AGMs.  591 
Conclusion  592 
In summary, increase oxidative stress and imbalances in pro and-anti-angiogenic growth 593 
mediators are independently associated with SHS. This was supported by an association 594 
of OS and AGMs with the individual SHS-specific domains. SHSQ-25 evaluation, 595 
which is a subjective non-invasive assessment for SHS can be used to identify increased 596 
OS and poor maternal vascular remodeling and thus inform clinicians of the need for 597 
antioxidant supplementation. Evaluation of SHSQ-25 may be an effective and time-598 
efficient tool that can augment other point-of-care testing especially in resource-limited 599 
facility in sub-Saharan African to improve poor health among normotensive pregnant 600 
women who suffer adverse health complaints without a diagnosable condition.  601 
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